Targeted drug delivery for cancer therapy: the other side of antibodies
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted drug delivery for cancer therapy: the other side of antibodies
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 5, Issue 1, Pages 70
Publisher
Springer Nature
Online
2012-11-09
DOI
10.1186/1756-8722-5-70
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Designing immunoconjugates for cancer therapy
- (2012) Serengulam V Govindan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations
- (2012) Tim M Illidge EXPERT OPINION ON BIOLOGICAL THERAPY
- High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism
- (2012) Yuji Mishima et al. INTERNATIONAL IMMUNOLOGY
- Antibody Phage Display Libraries: Contributions to Oncology
- (2012) Carmela Dantas-Barbosa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Monoclonal antibodies in hematological malignancies: Past, present and future
- (2012) I Tazi et al. Journal of Cancer Research and Therapeutics
- Phenotypic Detection of Clonotypic B Cells in Multiple Myeloma by Specific Immunoglobulin Ligands Reveals their Rarity in Multiple Myeloma
- (2012) Martin Trepel et al. PLoS One
- High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes
- (2012) Markus Heine et al. PLoS One
- Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation
- (2012) M. Jain et al. SCIENCE
- Intracellular Trafficking Considerations in the Development of Natural Ligand-Drug Molecular Conjugates for Cancer
- (2011) Dennis J. Yoon et al. ANNALS OF BIOMEDICAL ENGINEERING
- The transferrin receptor and the targeted delivery of therapeutic agents against cancer
- (2011) Tracy R. Daniels et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Aggregates in monoclonal antibody manufacturing processes
- (2011) María Vázquez-Rey et al. BIOTECHNOLOGY AND BIOENGINEERING
- Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma
- (2011) L. Alinari et al. BLOOD
- Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia
- (2011) Zdenka Haskova et al. BRITISH JOURNAL OF HAEMATOLOGY
- Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
- (2011) S. I. Rudnick et al. CANCER RESEARCH
- Peptide Aptamers with Biological and Therapeutic Applications
- (2011) J. Li et al. CURRENT MEDICINAL CHEMISTRY
- Advances in Methods for Therapeutic Peptide Discovery, Design and Development
- (2011) E. Pirogova et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Modulation of antibody effector function
- (2011) John R. Desjarlais et al. EXPERIMENTAL CELL RESEARCH
- Brentuximab Vedotin (SGN-35), an antibody–drug conjugate for the treatment of CD30-positive malignancies
- (2011) Antonio Gualberto EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia
- (2011) John L Reagan et al. Expert Review of Anticancer Therapy
- Immune microenvironments in solid tumors: new targets for therapy
- (2011) S. L. Shiao et al. GENES & DEVELOPMENT
- Brentuximab vedotin for the treatment of CD30+lymphomas
- (2011) Kelley V Foyil et al. Immunotherapy
- Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
- (2011) R. M. Sharkey et al. MOLECULAR CANCER THERAPEUTICS
- Development of a Peptide–Drug Conjugate for Prostate Cancer Therapy
- (2011) Wanyi Tai et al. MOLECULAR PHARMACEUTICS
- The Natural Cell-Penetrating Peptide Crotamine Targets Tumor Tissue in Vivo and Triggers a Lethal Calcium-Dependent Pathway in Cultured Cells
- (2011) Fabio D. Nascimento et al. MOLECULAR PHARMACEUTICS
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo
- (2011) Shanta Dhar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Substrate screening of protein kinases: Detection methods and combinatorial peptide libraries
- (2010) Mira Kim et al. BIOPOLYMERS
- Targeting neuropilin-1 in human leukemia and lymphoma
- (2010) K. Karjalainen et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
- (2010) Carol M Lee et al. BMC CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- (2010) Michinori Ogura et al. CANCER SCIENCE
- Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Ron J. Keizer et al. CLINICAL PHARMACOKINETICS
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Investigational antibody-drug conjugates for hematological malignancies
- (2010) Andrew G Polson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Synthetic constrained peptide selectively binds and antagonizes death receptor 5
- (2010) Johanna Vrielink et al. FEBS Journal
- Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma
- (2010) G. O. Negrea et al. HAEMATOLOGICA
- Cell culture processes for monoclonal antibody production
- (2010) Feng Li et al. mAbs
- Peptide-mediated targeted drug delivery
- (2010) Sumit Majumdar et al. MEDICINAL RESEARCH REVIEWS
- The Pharmacokinetics of Cell-Penetrating Peptides
- (2010) Dikran Sarko et al. MOLECULAR PHARMACEUTICS
- CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
- (2010) Stephen A. Beers et al. SEMINARS IN HEMATOLOGY
- Peptide drugs to target G protein-coupled receptors
- (2010) Kathrin Bellmann-Sickert et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
- (2010) Andrew V. Schally et al. Current Drug Delivery
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- Challenges in monoclonal antibody-based therapies
- (2009) Haritha Samaranayake et al. ANNALS OF MEDICINE
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas
- (2009) H.-P. Gerber et al. BLOOD
- The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy
- (2009) J Griggs et al. BRITISH JOURNAL OF CANCER
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- Antibody-Drug Conjugate Targets
- (2009) B. Teicher CURRENT CANCER DRUG TARGETS
- Synthetic therapeutic peptides: science and market
- (2009) Patrick Vlieghe et al. DRUG DISCOVERY TODAY
- Ocrelizumab: a step forward in the evolution of B-cell therapy
- (2009) Fariha Kausar et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Identification of novel peptide ligands for the cancer-specific receptor mutation EFGRvIII using a mixture-based synthetic combinatorial library
- (2008) Charlotte Lund Denholt et al. BIOPOLYMERS
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
- (2008) D. M. Goldenberg et al. BLOOD
- Tumor Cell Metabolism: Cancer's Achilles' Heel
- (2008) Guido Kroemer et al. CANCER CELL
- Immunoproteomics to identify tumor-associated antigens eliciting humoral response
- (2008) Zhirong Mou et al. CANCER LETTERS
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Antibody-based identification of cell surface antigens: targets for cancer therapy
- (2008) D LOO et al. CURRENT OPINION IN PHARMACOLOGY
- Phage Display Derived Therapeutic Antibodies
- (2008) Holger Thie et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
- (2008) M. E. Ackerman et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Specificity in cancer immunotherapy
- (2008) Andrea Schietinger et al. SEMINARS IN IMMUNOLOGY
- Design of a Tumor-Homing Cell-Penetrating Peptide
- (2007) Helena Myrberg et al. BIOCONJUGATE CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started